vs
Side-by-side financial comparison of Dianthus Therapeutics, Inc. (DNTH) and Vir Biotechnology, Inc. (VIR). Click either name above to swap in a different company.
Dianthus Therapeutics, Inc. is the larger business by last-quarter revenue ($284.0K vs $240.0K, roughly 1.2× Vir Biotechnology, Inc.). Dianthus Therapeutics, Inc. runs the higher net margin — -22687.3% vs -67975.4%, a 45288.1% gap on every dollar of revenue. On growth, Dianthus Therapeutics, Inc. posted the faster year-over-year revenue change (-78.6% vs -89.9%). Dianthus Therapeutics, Inc. produced more free cash flow last quarter ($-47.1M vs $-167.9M). Over the past eight quarters, Dianthus Therapeutics, Inc.'s revenue compounded faster (-44.6% CAGR vs -88.0%).
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
DNTH vs VIR — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0K | $240.0K |
| Net Profit | $-64.4M | $-163.1M |
| Gross Margin | — | — |
| Operating Margin | -24486.3% | -72267.9% |
| Net Margin | -22687.3% | -67975.4% |
| Revenue YoY | -78.6% | -89.9% |
| Net Profit YoY | -126.6% | 23.7% |
| EPS (diluted) | $-1.53 | $-1.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0K | — | ||
| Q3 25 | $396.0K | $240.0K | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | $1.2M | $3.0M | ||
| Q4 24 | $1.3M | $12.4M | ||
| Q3 24 | $2.2M | $2.4M | ||
| Q2 24 | $1.9M | $3.1M | ||
| Q1 24 | $874.0K | $56.4M |
| Q4 25 | $-64.4M | — | ||
| Q3 25 | $-36.8M | $-163.1M | ||
| Q2 25 | — | $-111.0M | ||
| Q1 25 | $-29.5M | $-121.0M | ||
| Q4 24 | $-28.4M | — | ||
| Q3 24 | $-25.2M | $-213.7M | ||
| Q2 24 | $-17.6M | $-138.4M | ||
| Q1 24 | $-13.7M | $-65.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 97.9% | ||
| Q2 24 | — | 98.3% | ||
| Q1 24 | — | 99.9% |
| Q4 25 | -24486.3% | — | ||
| Q3 25 | -10173.7% | -72267.9% | ||
| Q2 25 | — | -9754.3% | ||
| Q1 25 | -2852.7% | -4602.5% | ||
| Q4 24 | -2406.9% | — | ||
| Q3 24 | -1376.6% | -9718.7% | ||
| Q2 24 | -1191.8% | -5158.7% | ||
| Q1 24 | -2041.6% | -142.0% |
| Q4 25 | -22687.3% | — | ||
| Q3 25 | -9284.1% | -67975.4% | ||
| Q2 25 | — | -9139.9% | ||
| Q1 25 | -2537.5% | -3989.6% | ||
| Q4 24 | -2144.8% | — | ||
| Q3 24 | -1159.0% | -8979.7% | ||
| Q2 24 | -945.1% | -4500.1% | ||
| Q1 24 | -1573.0% | -115.8% |
| Q4 25 | $-1.53 | — | ||
| Q3 25 | $-0.97 | $-1.17 | ||
| Q2 25 | — | $-0.80 | ||
| Q1 25 | $-0.82 | $-0.88 | ||
| Q4 24 | $-0.76 | — | ||
| Q3 24 | $-0.74 | $-1.56 | ||
| Q2 24 | $-0.51 | $-1.02 | ||
| Q1 24 | $-0.54 | $-0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $404.3M | $497.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $493.4M | $796.1M |
| Total Assets | $530.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $404.3M | — | ||
| Q3 25 | $402.6M | $497.8M | ||
| Q2 25 | — | $598.7M | ||
| Q1 25 | $263.2M | $790.9M | ||
| Q4 24 | $275.2M | $901.0M | ||
| Q3 24 | $281.1M | $909.0M | ||
| Q2 24 | $360.7M | $1.1B | ||
| Q1 24 | $377.0M | $1.1B |
| Q4 25 | $493.4M | — | ||
| Q3 25 | $546.5M | $796.1M | ||
| Q2 25 | — | $947.5M | ||
| Q1 25 | $328.6M | $1.0B | ||
| Q4 24 | $352.5M | $1.2B | ||
| Q3 24 | $337.9M | $1.2B | ||
| Q2 24 | $358.2M | $1.4B | ||
| Q1 24 | $372.7M | $1.5B |
| Q4 25 | $530.9M | — | ||
| Q3 25 | $577.4M | $1.0B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | $348.6M | $1.3B | ||
| Q4 24 | $374.0M | $1.4B | ||
| Q3 24 | $354.2M | $1.5B | ||
| Q2 24 | $369.0M | $1.7B | ||
| Q1 24 | $382.5M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-47.0M | $-167.6M |
| Free Cash FlowOCF − Capex | $-47.1M | $-167.9M |
| FCF MarginFCF / Revenue | -16591.9% | -69952.9% |
| Capex IntensityCapex / Revenue | 48.6% | 132.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-132.8M | $-824.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-47.0M | — | ||
| Q3 25 | $-30.6M | $-167.6M | ||
| Q2 25 | — | $-120.2M | ||
| Q1 25 | $-27.6M | $-78.1M | ||
| Q4 24 | $-27.4M | $-446.4M | ||
| Q3 24 | $-21.3M | $-171.5M | ||
| Q2 24 | $-14.5M | $-77.8M | ||
| Q1 24 | $-14.9M | $-109.4M |
| Q4 25 | $-47.1M | — | ||
| Q3 25 | $-30.6M | $-167.9M | ||
| Q2 25 | — | $-122.8M | ||
| Q1 25 | $-27.7M | $-79.7M | ||
| Q4 24 | $-27.5M | $-453.7M | ||
| Q3 24 | $-21.3M | $-174.2M | ||
| Q2 24 | $-14.5M | $-78.5M | ||
| Q1 24 | $-15.0M | $-111.3M |
| Q4 25 | -16591.9% | — | ||
| Q3 25 | -7717.2% | -69952.9% | ||
| Q2 25 | — | -10111.8% | ||
| Q1 25 | -2377.8% | -2630.1% | ||
| Q4 24 | -2072.0% | -3666.2% | ||
| Q3 24 | -980.3% | -7321.3% | ||
| Q2 24 | -780.7% | -2553.3% | ||
| Q1 24 | -1713.2% | -197.4% |
| Q4 25 | 48.6% | — | ||
| Q3 25 | 1.3% | 132.1% | ||
| Q2 25 | — | 209.1% | ||
| Q1 25 | 2.1% | 53.7% | ||
| Q4 24 | 2.3% | 59.0% | ||
| Q3 24 | 1.2% | 116.3% | ||
| Q2 24 | 0.9% | 21.7% | ||
| Q1 24 | 3.7% | 3.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
